Funds and ETFs NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 01:51:12 2023-11-29 pm EST Intraday chart for NovoCure Limited 5-day change 1st Jan Change
12.36 USD +1.31% +3.19% -83.23%

ETFs positioned on NovoCure Limited

Name Weight AuM 1st Jan change Investor Rating
0.90% 69 M€ -3.54%
0.88% 277 M€ -16.61% -
0.81% 0 M€ 0.00% -
0.71% 0 M€ 0.00% -
0.57% 45 M€ -5.52%
0.57% 36 M€ -11.69% -
0.48% 31 M€ +4.25% -
0.42% 55 M€ -12.98% -
0.39% 69 M€ -17.93%
0.36% 3 M€ -9.68%
0.35% 909 M€ -10.51% -
0.23% 584 M€ -3.06% -
0.23% 47 M€ +1.86%
0.22% 34 M€ -9.43% -
0.22% 329 M€ -12.76%
0.22% 3 M€ -5.16% -
0.22% 6,059 M€ -8.83%
0.20% 15 M€ -8.97%
0.19% 26 M€ +9.30% -
0.19% 4,371 M€ -4.89%
0.17% 31 M€ -.--%
0.16% 0 M€ 0.00% -
0.16% 0 M€ -.--% -
0.16% 566 M€ +4.54%
0.16% 131 M€ -2.56%
0.14% 18 M€ -10.38% -
0.11% 337 M€ +9.82%
0.10% 11,759 M€ +9.15%
0.09% 0 M€ -.--% -
0.09% 1,337 M€ +6.89%
0.09% 3 M€ +7.00%
0.08% 10 M€ -0.99% -
0.08% 486 M€ +15.36%
0.08% 20 M€ +14.82% -
0.08% 10,995 M€ +16.14%
0.07% 8,594 M€ +5.87%
0.06% 90 M€ +7.85%
NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company's key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
12.20USD
Average target price
26.14USD
Spread / Average Target
+114.29%
Consensus
  1. Stock
  2. Equities
  3. Stock NovoCure Limited - Nasdaq
  4. Funds and ETFs NovoCure Limited
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer